Skip to main content

Neuphoria Therapeutics Inc.

NEUP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001191070

No open-market purchases or sales by Neuphoria Therapeutics Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $8.71M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +3 vs. previous quarter
22
13F valueReported value at the end of Q2 2026
$8.71M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding NEUP, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding NEUP at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Neuphoria Therapeutics Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 23, 2025 (view filing)7:49 PM ETOct 212 daysNichols Weston and 1 other10% OwnerPPurchaseCommon stock, $0.00001 par value per share+639.1K$5.14+$3.28M+270.6%875.3K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Neuphoria Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 22 holders
Institutions holding NEUP in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Lynx1 Capital Management LP875,328$3.83M0.44%00.0%Unchanged
AdvisorShares Investments LLC252,909$1.11M0.13%+97,542+62.8%Added
Vanguard Capital Management LLC173,488$758.1K0.00%+74,972+76.1%Added
Shay Capital LLC155,822$680.9K0.08%+4,812+3.2%Added
Balyasny Asset Management LLC142,228$621.5K0.00%+450.0%Added
Citadel Advisors LLC72,559$317.1K0.00%+53,228+275.4%Added
Geode Capital Management, LLC49,516$216.4K0.00%−2,491−4.8%Reduced
Ikarian Capital, LLC47,443$207.3K0.03%00.0%Unchanged
Vanguard Fiduciary Trust Co33,806$147.7K0.00%+217+0.6%Added
ADAR1 Capital Management, LLC30,000$131.1K0.01%00.0%Unchanged